PVpharm provides support to the UCLouvain for COVID-19 phase II study project

  • Post published:March 30, 2021

We are happy to announce that PVpharm has been selected to provide safety support for a research project coordinated by the Catholic University of Louvain (UCLouvain) for a COVID-19 Phase II study. PVpharm will be supporting the clinical safety function with pharmacovigilance, report submission, safety report writing, Eudravigilance, CTIS and other PV and administrative related activities. PVpharm is providing support to Sponsors of clinical trials in the EU, please read more about our Pharmacovigilance services at https://pvpharm.com/pharmacovigilance/ Please contact us with any question https://pvpharm.com/contact/

Continue ReadingPVpharm provides support to the UCLouvain for COVID-19 phase II study project

PVpharm and Azierta agrees on a strategic alliance in Pharmacovigilance

  • Post published:March 29, 2021

PVpharm and Azierta agrees on a strategic alliance in the field of Pharmacovigilance. This alliance will make it possible to jointly design and commercialize advanced pharmacovigilance services both for the Spanish market and internationally. The alliance signed places both companies in a position of reference in the health consulting sector in the field of pharmacovigilance in Spain, currently providing its services to more than 2,000 clients that represent 80% of the pharmaceutical industry and a share close to 25 % of the market for pharmacovigilance services. PVpharm is supporting and helping organizations to improve their quality processes in Pharmacovigilance. Please…

Continue ReadingPVpharm and Azierta agrees on a strategic alliance in Pharmacovigilance